Glaxo Consumer Finds Growth Groove Via Innovation, Acquisitions, Expansion
This article was originally published in The Tan Sheet
GlaxoSmithKline's consumer health care business appears back on track with 8 percent growth in the firm's latest earnings period, a year after it reported flat consumer sales hurt by the disappointing U.S. performance of weight-loss drug alli
You may also be interested in...
GlaxoSmithKline is replacing the conventional toothpaste tube with a canister like those used for shaving products to deliver its new Aquafresh and Sensodyne products with "twice the foam volume as ordinary toothpaste.
Alli is off to the races in Europe, where it is generating high sales since launching in April, GlaxoSmithKline says
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion by acquiring Stiefel Laboratories and creating a global specialist business across Rx and OTC drugs